Compare Garmin Ltd. (GRMN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Viatris Inc — how do they compare? Garmin Ltd. trades at $268.36 (market cap $51.77B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Garmin Ltd. is far larger — about 2.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Viatris Inc for 57 Days on average.
| GRMN | VTRS | |
|---|---|---|
Market Cap | $51.77B | $20.03B |
Volume | 961,398 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $313.16 | $18.27 |
52-Week Low | $187.10 | $9.74 |
Typical Hold Time | 83 Days | 57 Days |
Enterprise Value | $49.28B | $32.15B |
Dividend Yield | 1.56% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.36, down 2.82% on the day, reflecting a recent bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.81 surpassing the $2.30 expectation. Revenue and net income have shown steady growth, reaching $7.25 billion and $1.66 billion respectively in 2025. Positive news includes product awards and new feature rollouts, yet analyst consensus remains heavily weighted toward Hold.
The outlook balances robust profitability and growth against a cautious Wall Street sentiment and near-term technical weakness. Investment opportunity lies in the company's strong execution and product innovation, but risks include competitive pressures and market volatility. The consensus price target of $320.25 suggests significant potential upside from the current price if positive earnings trends continue.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
